Finding new ways to overcome resistance to lung cancer treatments targeting KRAS mutations
Official title: Overcoming resistance to KRAS inhibitors through a fragment-based chemoproteomics approach
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10722113 · Data updated 2026-11-12
This study is looking for better treatments for lung cancer patients with a specific gene mutation that makes their cancer hard to treat, by finding new ways to target the cancer and create simpler drugs that work better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $433,256 |
| NIH project number | 1R21CA282568-01 |
| Project ID | NIH-10722113 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are lung cancer patients with KRASG12C mutations who have experienced resistance to current therapies.
✕Less likely to help
Patients without KRASG12C mutations or those who have not undergone treatment with KRAS inhibitors may not benefit from this research.
What this research studies
This research focuses on improving treatments for lung cancer patients with KRASG12C mutations, which are often resistant to current therapies. The team will use innovative techniques to identify new targets and develop smaller, simpler drug-like molecules that can effectively bind to these targets. By studying cell line models that mimic resistance mechanisms, the researchers aim to uncover why some patients do not respond to treatment and how to enhance the effectiveness of existing therapies. This approach could lead to the discovery of new drugs that can overcome resistance and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients who currently do not respond to existing KRAS inhibitors.
How similar studies have gone: Other research has shown promise in targeting KRAS mutations, but this specific approach using fragment-based chemoproteomics is relatively novel.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Haura, Eric B. — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Haura, Eric B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.